Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (4252)	5/7/1998 12:13:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

Ralf: Difficult molecule to make, and contract manufacturing. However, therein is the rub..... lots of room for increased profit at the same revenues. Rick

To: Spekulatius who wrote (4252)	5/7/1998 10:17:00 AM
From: ALL	Read Replies (3) \| Respond to of 6136

Ralf, Keep in mind that gross margins for Viracept include European sales and costs, which tend to distort actual margins because AGPH sells Viracept to Roche for most international sales at cost + about 5% and receives royalties in turn. In the most recent quarter, US Viracept sales were $92.8 million and $19.2 million internationally. Adjusting for international sales, gross (US) margins were 66 to 67%.

To: Spekulatius who wrote (4252)	5/7/1998 12:15:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Ralf: Margin question aside, I think you hit the nail on the head in terms of market nervousness and AGPH. Until we receive something solid to grasp on to regarding the pipeline (could be soon), scrip data will likely control the short term trends. Could go either way. I would guess many potential investors are not thrilled by the runup to 40 and rapid pullback to 35. The world is much more aware of AGPH now. We'll have to see what kind of spin, if any is put on the situation in weekend writeups. If the results of earlier trials on AG3340 are taken well, a deal with another company is announced, or other positive data on the pipeline surfaces, it could give us the boost over 40. Hard to say when we'll see those results though, in the meantime IMO, if scrip data falters, the 52 week low in the 27-28 range isn't out of the realm of reality either. It would probably be stubborn at the 30 level. sf